A Study of Bumetanide for the Treatment of Children With Autism Spectrum Disorder：a Randomized Double-blind Placebo-controlled Trial
Overview
- Phase
- Phase 2
- Intervention
- Bumetanide
- Conditions
- Autism Spectrum Disorder
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Childhood Autism Rating Scale(CARS)
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The investigators are going to carry out a randomized double-blind placebo-controlled trial to study the efficiency and mechanism of bumetanide on the treatment of children with Autism Spectrum Disorder.
Detailed Description
In consideration of the increasing number of autistic children and poor intervention effect in China, it is an urgent to find some effective medicine. Some studies have reported bumetanide, a classic diuretic, could improve autistic behaviors in both animal model and humans; while the efficiency of bumetanide on Chinese autistic chilren is unkonwn and the underlying mechanisms remain unfolding. The investigators aim at investigating whether bumetanide would improve the clinical symptoms in Chinese children with autism within a safe dosage and further study the physiological mechanism beneath.The investigators will regularly assess the participants' autism-related symptoms during medication, as well as the adverse effects of each patient. The investigators will carry out genome-wide association analysis (GWAS) from blood sample, related metabolites in nervous system and compare the concentration of the neurotransmitter in autistic brain before and after 3 months' treatmeat,and also will collect the EEG signal in autistic chilldren when the participants performing certain tasks before and after 3 months' treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The patients, aged from 3 to 6 years old, were given the diagnosis of ASD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) , by a team of autism experts; Scores for Children Autism Rating Scale (CARS) were more than 30; Signed Informed Consents were provided by parents.
Exclusion Criteria
- •Liver and kidney dysfunction; With a history of allergy to sulfa drugs; abnormal ECG; chromosomal abnormality; suffering from nervous system diseases (such as epilepsy, schizophrenia, and so on); using the melatonin treatment for sleep disorders or withdrawal less than three weeks.
Arms & Interventions
Bumetanide group
Double-blind phase: in the first 3 months, patients will receive the experimental treatment - bumetanide, oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, all the patients will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
Intervention: Bumetanide
Control group
Double-blind phase: in the first 3 months, patients will receive the placebo - oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, patients in this group will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
Intervention: Placebo
Outcomes
Primary Outcomes
Childhood Autism Rating Scale(CARS)
Time Frame: Day 0 and Day 90
CARS is a behaviour-rating scale used to assess the presence and severity of the symptoms of autism spectrum disorder
Secondary Outcomes
- Clinical Global Impressions Scale (CGI)(Day 0 and Day 90)
- Social Responsiveness Scale (SRS)(Day 0 and Day 90)
- Autism Diagnostic Observation Schedule (ADOS)(Day 0 and Day 90)
- Short Sensory Profile Report(Day 0 and Day 90)
- Symbolic Play Test(Day 0 and Day 90)
- Chinese Communicative Development Inventory(Day 0 and Day 90)